Title of Dataset:
Research data supporting "Inhibition of Indole Production Increases the Activity of Quinolone Antibiotics against E. coli Persisters"
(Scientific Reports, 2020)

Date and location for data collection:
These data were collected in the period between Oct 2016 to December 2019 at the Department of Genetics (University of Cambridge, UK).

People responsible for collecting the data:
The data were collected by:
Dr Ashraf Zarkan (University of Cambridge Department of Genetics, email: maa77@cam.ac.uk)
Miss Marta Matuszewska (University of Cambridge, Department of Vetrinary Medicine, email: mm2211@cam.ac.uk)
Mr Stephen Trigg (University of Cambridge, Department of Biochemistry, email: sbt27@cam.ac.uk)
Mrs Meng Zhao (Henan Centre for Disease Control and Prevention, China, email: zhangmeng7311@126.com)
Miss Daaniyah Belgami (The Oxford College of Engineering, India, email: daaniyahbelgami@yahoo.com)
Mr Cameron Croft (University of Cambridge Department of Genetics, email: cc994@cam.ac.uk)
Miss Sawssen Elouisi (Faculty of Fundamental and Biomedical Sciences, Paris Descartes University, France, email: sawssen.e@hotmail.fr)  

Contact person for questions:
Please contact Dr Ashraf Zarkan or Miss Marta Matuszewska.

Funding:
Dr Ashraf Zarkan was supported by funding from  the Leverhulme Trust, UK (RPG-2015-184) and Innovate UK (SBRI: Antimicrobial Resistance in Human, 971621).
Mr Cameron Croft was supported by funding from Innovate UK (SBRI: Antimicrobial Resistance in Human, 971621). 


Data and file overview:

1) Excel file (.xlsx) labelled as Zarkan et al 2020_Data:

Nalidixic Acid.
Data of three biological replicates of E. coli BW25113 WT & tnaA KO treated with x100 MIC Nalidixic Acid, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Ciprofloxacin.
Data of three biological replicates of E. coli BW25113 WT & tnaA KO treated with x100 MIC Ciprofloxacin, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Levofloxacin.
Data of three biological replicates of E. coli BW25113 WT & tnaA KO treated with x100 MIC Levofloxacin, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Moxifloxacin.
Data of three biological replicates of E. coli BW25113 WT & tnaA KO treated with x100 MIC Moxifloxacin, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Novobiocin.
Data of three biological replicates of E. coli BW25113 WT & tnaA KO treated with x100 MIC Novobiocin, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Ciprofloxacin with CCCP & DNP.
Data of three biological replicates of E. coli BW25113 tnaA KO treated x100 MIC ciprofloxacin after applying a brief treatment (20 min) with 100 uM CCCP or 800 uM DNP, showing the pecentage of survival (calculated by percentage of cfu count before and after antibiotic treatment).

Ratio of Survival WT vs tnaA KO.
Data of the calculated ratio of survival in the plateau of E. coli BW25113 WT/tnaA KO after treatment with x100 MIC Nalidixic Acid, Ciprofloxacin, Levofloxacin & Moxifloxacin.

Ratio of Survival Persistent.
Data of the calculated ratio of survival in the plateau of E. coli tnaA KO + 0.5 mM indole supplementation/tnaA KO after treatment with x100 MIC Nalidixic Acid, Ciprofloxacin, Levofloxacin & Moxifloxacin.

Ratio of Survival Pulse.
Data of the calculated ratio of survival in the plateau of E. coli tnaA KO + indole pulse mimic (5 mM for 20 min) /tnaA KO after treatment with x100 MIC Nalidixic Acid, Ciprofloxacin, Levofloxacin & Moxifloxacin.

Indole Assay Standard Curve.
Data of a series of increased indole concentrations treated by Kovacs reagents and assayed at OD = 530 nm. The data are plotted to generate a standard curve.

Indole Assay Measurments.
Data of three biological replicates of E. coli BW25113 supernatant before and after treatment with x100 MIC. The supernatants were treated by Kovacs reagents and assayed at OD = 530 nm. Indole concentration was calculated from the standard curve. 


2) .zip file labelled as Flow Cytometry.
.fcs flow cytometry data of GFP expression in E. coli BW25113 WT & TnaA-GFP treated with x100 MIC Ciprofloxacin.

Negative Control.
Sample of E. coli BW25113 WT (GFP -) without ciprofloxacin treatment.

Positive Control.
Sample of E. coli BW25113 TnaA-GFP (GFP +) without ciprofloxacin treatment.  

Time_10min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 10 min treatment with x100 MIC ciprofloxacin. 

Time_20min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 20 min treatment with x100 MIC ciprofloxacin. 

Time_30min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 30 min treatment with x100 MIC ciprofloxacin.

Time_40min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 40 min treatment with x100 MIC ciprofloxacin.

Time_50min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 50 min treatment with x100 MIC ciprofloxacin.

Time_60min.
Sample of E. coli BW25113 TnaA-GFP (GFP +) after 60 min treatment with x100 MIC ciprofloxacin.